- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.09. | RenovoRx auf H.C. Wainwright Konferenz: Kommerzieller Erfolg wächst, entscheidende Studiendaten stehen aber noch aus | 2 | Investing.com Deutsch | ||
| RENOVORX Aktie jetzt für 0€ handeln | |||||
| 01.09. | Biotech Stocks At 52-Week Highs - RenovoRx +15%, Evolus, Crinetics Pharmaceuticals, Apogee Therapeutics | 821 | AFX News | CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - The following biotech stocks reached a 52-week high on August 31, 2026, driven by achieving new regulatory milestones or an upcoming acquisition.RenovoRx... ► Artikel lesen | |
| 31.08. | Biotech Stocks At 52-Week Highs - RenovoRx +12%, BlossomHill Therapeutics, Revvity, AtriCure, Biofrontera Inc. | 638 | AFX News | WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on August 28, 2026, as various clinical trials reported initial data and companies reached certain regulatory milestones.RenovoRx... ► Artikel lesen | |
| 25.08. | RenovoRx, Inc.: RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP Platform's Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer | 2 | GlobeNewswire (USA) | ||
| 21.08. | RenovoRx regains Nasdaq compliance | 1 | Seeking Alpha | ||
| 21.08. | RenovoRx regains Nasdaq minimum bid price compliance | 1 | Investing.com | ||
| 21.08. | RenovoRx erfüllt wieder NASDAQ-Mindestkursanforderung | 3 | Investing.com Deutsch | ||
| 21.08. | RenovoRx, Inc.: RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement | 299 | GlobeNewswire (Europe) | MOUNTAIN VIEW, Calif., Aug. 21, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or "the Company") (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and... ► Artikel lesen | |
| 20.08. | RenovoRx, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 20.08. | RenovoRx receives U.S. patent allowance for cancer device | 5 | Investing.com | ||
| 20.08. | RenovoRx, Inc.: RenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath, an Advanced Dual-Occlusion Catheter, for Targeted Therapeutic Drug-Delivery for Cancer Treatment | 272 | GlobeNewswire (Europe) | MOUNTAIN VIEW, Calif., Aug. 20, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or "the Company") (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and... ► Artikel lesen | |
| 13.08. | RenovoRx, Inc. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 12.08. | RenovoRx, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 11.08. | RenovoRx, Inc.: RenovoRx Achieves Major Milestone with Full Enrollment in Phase III TIGeR-PaC Trial for Locally Advanced Pancreatic Cancer | 1.221 | GlobeNewswire (Europe) | MOUNTAIN VIEW, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or "the Company") (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and... ► Artikel lesen | |
| 11.08. | EXCLUSIVE: Renovorx Advances Its Targeted Pancreatic Cancer Therapy, Pivotal Data Expected in 2027 | 1 | Benzinga.com | ||
| 06.08. | RenovoRx, Inc.: RenovoRx Announces First Commercial Clinical Use of RenovoCath in Sarcoma Patient Treatment, Marking Expansion of Targeted Drug-Delivery Device to Other Solid Tumors | 288 | GlobeNewswire (Europe) | MOUNTAIN VIEW, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or "the Company") (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and... ► Artikel lesen | |
| 04.08. | RenovoRx, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 30.06. | RenovoRx, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 30.06. | RenovoRx, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 28.05. | RenovoRx Says FDA Grants Orphan Drug Status For Oxaliplatin To Treat Pancreatic Cancer | 1 | RTTNews |
1 2 3 Weiter >>
43 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 83,80 | +0,18 % | Wolfram, Bier und Impfstoffe: Was Almonty Industries, Heineken und BioNTech verbindet | Ein Rohstoffkonzern, dessen Aktienkurs sich innerhalb eines Jahres verdreifacht hat, weil ein unscheinbares Schwermetall zur begehrten Mangelware wird. Ein Brauereiriese, der seit Jahrzehnten eine Cash-Maschine... ► Artikel lesen | |
| MODERNA | 134,16 | +0,12 % | Moderna und BioNTech lassen Corona endgültig hinter sich | Aus dem alten Duell der beiden Corona-Gewinner ist ein neuer Wettbewerb geworden. Moderna erlebt nach überzeugenden Phase-3-Daten für eine personalisierte Krebstherapie eine spektakuläre Neubewertung.... ► Artikel lesen | |
| VALNEVA | 2,863 | +1,02 % | Valneva-Aktie im Check am 20.09. (10:36 Uhr): Meine aktuelle Lageeinschätzung | ||
| AMGEN | 335,15 | -0,16 % | Amgen: FDA Approves Update To IMDELLTRA Prescribing Information, Cuts Monitoring Time For Two Doses | THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) announced the FDA approved an update to the IMDELLTRA Prescribing Information that substantially reduces the recommended monitoring time for the first... ► Artikel lesen | |
| NOVAVAX | 8,670 | -1,37 % | Novavax: Langfristige Aussichten im Spannungsfeld von Innovation und Konkurrenz | ||
| BIOGEN | 189,04 | +0,74 % | Biogen Inc.: Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN | EMPAVELI-treated adolescents achieved a 75% relative reduction in proteinuria within 6 months versus placebo EMPAVELI is the only approved treatment for adolescents with C3G and primary IC-MPGN, based... ► Artikel lesen | |
| ILLUMINA | 210,00 | +0,70 % | Biotech Stocks At 52-Week Highs - BlossomHill Therapeutics +18% On Positive Trial Data, Adaptive Biotechnologies, Illumina, CeriBell, Neogen | SAN DIEGO (dpa-AFX) - The following biotech stocks reached a 52-week high on September 16, 2026, driven by positive results from clinical trials or an upcoming conference participation.BlossomHill... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 49,155 | -0,17 % | CRISPR Therapeutics auf Morgan Stanley Konferenz: Pipeline-Erweiterung und kommerzielle Fortschritte | ||
| PALATIN TECHNOLOGIES | 10,900 | +0,37 % | Wall Street Wire: StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It | Rare-endocrine buyers have paid roughly $2.9 billion and approximately $10.0 billion for acquisitions in this area over the past four months. IMCIVREE, the only approved MC4R agonist for acquired... ► Artikel lesen | |
| OCUGEN | 0,927 | -0,11 % | Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration | The single global Phase 3 trial, ArMaDa3 (NCT07770828), is the first pivotal gene therapy trial in geographic atrophy (GA)U.S. Food and Drug Administration (FDA) granted OCU410 Regenerative Medicine... ► Artikel lesen | |
| VIKING THERAPEUTICS | 25,100 | -0,59 % | Wall Street Sees a Huge Rebound for Viking Therapeutics. Here's Why Analysts Are So Optimistic. | ||
| INTELLIA THERAPEUTICS | 10,360 | -2,08 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million | CAMBRIDGE, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing... ► Artikel lesen | |
| TEMPUS AI | 67,70 | -0,09 % | Tempus AI stock is soaring: does it have more upside to go? | ||
| VIVORYON THERAPEUTICS | 1,095 | +0,46 % | Vivoryon Therapeutics N.V. to Hold its 2026 Annual General Meeting on September 29, 2026 | Vivoryon Therapeutics N.V. to Hold its 2026 Annual General Meeting on September 29, 2026
Halle (Saale) / Munich, Germany, August 18, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7)... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 7,490 | 0,00 % | BioCryst Pharmaceuticals, Inc.: BioCryst Announces Approval of ORLADEYO for Pediatric HAE Patients in Japan | - Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2 to RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc.... ► Artikel lesen |
Das Unternehmen RENOVORX INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,005 (+0,30 %) liegt der Kurs bei 1,695 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu RENOVORX INC finden Sie auf Wallstreet Online.